These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9561237)

  • 1. Development and testing of inhibitors of Candida aspartic proteinases.
    Pichová I; Brozková K; Pavlícková L; Fusek M; Krízová I; Ruml T; Soucek M
    Adv Exp Med Biol; 1998; 436():329-33. PubMed ID: 9561237
    [No Abstract]   [Full Text] [Related]  

  • 2. Extracellular aspartic proteinases from Candida yeasts.
    Fusek M; Smith E; Foundling SI
    Adv Exp Med Biol; 1995; 362():489-500. PubMed ID: 8540363
    [No Abstract]   [Full Text] [Related]  

  • 3. Secreted aspartic proteases of Candida albicans, Candida tropicalis, Candida parapsilosis and Candida lusitaniae. Inhibition with peptidomimetic inhibitors.
    Pichová I; Pavlícková L; Dostál J; Dolejsí E; Hrusková-Heidingsfeldová O; Weber J; Ruml T; Soucek M
    Eur J Biochem; 2001 May; 268(9):2669-77. PubMed ID: 11322888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of N-chlorotaurine on viability and production of secreted aspartyl proteinases of Candida spp.
    Nagl M; Gruber A; Fuchs A; Lell CP; Lemberger EM; Borg-Von Zepelin M; Würzner R
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1996-9. PubMed ID: 12019124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tetracycline-inducible expression of individual secreted aspartic proteases in Candida albicans allows isoenzyme-specific inhibitor screening.
    Staib P; Lermann U; Blass-Warmuth J; Degel B; Würzner R; Monod M; Schirmeister T; Morschhäuser J
    Antimicrob Agents Chemother; 2008 Jan; 52(1):146-56. PubMed ID: 17954688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of pepstatin A on the virulence factors of Candida albicans strains isolated from vaginal environment of patients in three different clinical conditions.
    Consolaro ME; Gasparetto A; Svidzinski TI; Peralta RM
    Mycopathologia; 2006 Aug; 162(2):75-82. PubMed ID: 16897584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, inhibition studies, and molecular modeling of pepstatin analogues addressing different secreted aspartic proteinases of Candida albicans.
    Cadicamo CD; Mortier J; Wolber G; Hell M; Heinrich IE; Michel D; Semlin L; Berger U; Korting HC; Höltje HD; Koksch B; Borelli C
    Biochem Pharmacol; 2013 Apr; 85(7):881-7. PubMed ID: 23262278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Degradation of human subendothelial extracellular matrix by proteinase-secreting Candida albicans.
    Morschhäuser J; Virkola R; Korhonen TK; Hacker J
    FEMS Microbiol Lett; 1997 Aug; 153(2):349-55. PubMed ID: 9271862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The secreted aspartic proteinases as a new target in the therapy of candidiasis.
    Bein M; Schaller M; Korting HC
    Curr Drug Targets; 2002 Oct; 3(5):351-7. PubMed ID: 12182226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insight into the structural similarity between HIV protease and secreted aspartic protease-2 and binding mode analysis of HIV-Candida albicans inhibitors.
    Calugi C; Guarna A; Trabocchi A
    J Enzyme Inhib Med Chem; 2013 Oct; 28(5):936-43. PubMed ID: 22803674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Invasion of Candida albicans correlates with expression of secreted aspartic proteinases during experimental infection of human epidermis.
    Schaller M; Schackert C; Korting HC; Januschke E; Hube B
    J Invest Dermatol; 2000 Apr; 114(4):712-7. PubMed ID: 10733678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Candida albicans aspartyl protease inhibitor. II. A new pepstatin-ahpatinin group inhibitor, YF-044P-D.
    Sato T; Shibazaki M; Yamaguchi H; Abe K; Matsumoto H; Shimizu M
    J Antibiot (Tokyo); 1994 May; 47(5):588-90. PubMed ID: 8040057
    [No Abstract]   [Full Text] [Related]  

  • 13. A new plate assay for detecting inhibitors of Candida aspartyl proteinase.
    Dikshit VR; Desai PD
    J Antibiot (Tokyo); 2000 Feb; 53(2):201-3. PubMed ID: 10805583
    [No Abstract]   [Full Text] [Related]  

  • 14. Replacement of isobutyl by trifluoromethyl in pepstatin A selectively affects inhibition of aspartic proteinases.
    Binkert C; Frigerio M; Jones A; Meyer S; Pesenti C; Prade L; Viani F; Zanda M
    Chembiochem; 2006 Jan; 7(1):181-6. PubMed ID: 16307463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Purification and properties of three intracellular proteinases from Candida albicans.
    Portillo F; Gancedo C
    Biochim Biophys Acta; 1986 Apr; 881(2):229-35. PubMed ID: 3513844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV proteinase inhibitors: do they really work against Candida in a clinical setting?
    Cassone A; Cauda R
    Trends Microbiol; 2002 Apr; 10(4):177-8. PubMed ID: 11912024
    [No Abstract]   [Full Text] [Related]  

  • 17. Crystallization of inhibited aspartic proteinase from Candida albicans.
    Cutfield S; Marshall C; Moody P; Sullivan P; Cutfield J
    J Mol Biol; 1993 Dec; 234(4):1266-9. PubMed ID: 8263928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pepstatin-insensitive carboxyl proteinases from prokaryotes. Catalytic residues and substrate specificities.
    Oda K; Takahashi S; Ito M; Dunn BM
    Adv Exp Med Biol; 1998; 436():349-53. PubMed ID: 9561241
    [No Abstract]   [Full Text] [Related]  

  • 19. Anti-fungal therapy at the HAART of viral therapy.
    Munro CA; Hube B
    Trends Microbiol; 2002 Apr; 10(4):173-7. PubMed ID: 11912023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered adherence in strains of Candida albicans harbouring null mutations in secreted aspartic proteinase genes.
    Watts HJ; Cheah FS; Hube B; Sanglard D; Gow NA
    FEMS Microbiol Lett; 1998 Feb; 159(1):129-35. PubMed ID: 9485603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.